Join the club for FREE to access the whole archive and other member benefits.

Edouard Debonneuil

Chief Data Officer at Natixis Investment Managers and a Founding Member of the International Longevity Alliance

Graduated from Ecole Centrale Paris in 2002 and UCLA in 2003, engineer, biologist, quant, life actuary, data scientist, PhD in health economics, with high functions in large companies, large experience in the financial industry, as well as a start-up CEO experience in data insights for health,

Edouard has been a Founding Member of the International Longevity Alliance, and then served as an ILA Board Member on behalf of French NGO “Longevite&Sante”. Former epidemiology and biology of aging researcher at UCLA,the Pasteur Institute and Inserm, then life actuary specialised in biometric risks. President of the French branch (“Longévité Santé”). Member of Heales (Healthy Life Extension Society), European NGO based in Brussels. Strong supporter of GRG and Longecity. Co-author of a book called “Longevity Risk”. Key vision: mouse lifespan tests and human statistics to find out what prolongs life and health.

Edouard organized and worked as Head of R&D/Innovation in AXA Global Life, which provided grants to many researchers studying aging.

Edouard prioritized mouse lifespan testing within ILA, and founded the Major Mouse Testing Program. As a result he helped to organize the first mouse studies in MMTP. (In 2015 Steve Hill assumed leadership of the MMTP and with his team successfully crowdfunded a large research project in collaboration with Dr.Alexandra Stolzing at Leipzig University).

Visit website: https://longevityalliance.org/employee/edouard-debonneuil-france-paris/

 edouard-debonneuil-5484932

 edebonneuil

See also: Institute International Longevity Alliance (ILA) - Facilitating faster development and implementation of life-extending technologies to ensure healthy longevity for all

Details last updated 03-Dec-2022

Edouard Debonneuil News

In silico drug repurposing method and insurance data analysis identifies Sildenafil as potential therapy for Alzheimer’s disease

In silico drug repurposing method and insurance data analysis identifies Sildenafil as potential therapy for Alzheimer’s disease

Live Forever Club - 06-Dec-2022

Current research identified drug candidate, big data analysis confirmed an association, and lab work demonstrated a biological effect